Journals / Ege Tıp Dergisi / 2011 / Cilt: 50 - Sayı: 3

Octreotide in addition to antibiotic treatment may prevent ultrafiltration failure in experimental peritonitis model

Antibiyotik tedavisine ek olarak oktreotid uygulanması deneysel peritonit modelinde ultrafiltrasyon yetmezliğini engelleyebilir

Pages
167–173
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

Conclusion: In conclusion, adding OCT in dialysate, may help to prevent peritonitis induced UF failure and preserve peritoneal viability by inhibiting acute cytokines over-expression and cell infiltration during peritonitis.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Aim: Ultrafiltration (UF) failure is usually associated with peritoneal dialysis (PD) peritonitis.
📊
Key Findings & Data:Material and Methods: Forty non-uremic female rats, were divided into four groups receiving no treatment (Control, n=12); a peritonitis group which received 1.5ml suspension of E.Coli (107CFU/ml)(E.Coli, n=12); an antibiotic group which received 1.5ml suspension of E.Coli (107CFU/ml)+antibiotic (AB, cefazoline 50 mg/kg)(E.Coli+AB, n=8) and a OCT group which received E.Coli+AB+50μg/kg OCT intraperitoneally (E.Coli+AB+OCT, n=8).
💡
Conclusion & Impact:Conclusion: In conclusion, adding OCT in dialysate, may help to prevent peritonitis induced UF failure and preserve peritoneal viability by inhibiting acute cytokines over-expression and cell infiltration during peritonitis.
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:Domain Parameters

Abstract

Aim: Ultrafiltration (UF) failure is usually associated with peritoneal dialysis (PD) peritonitis. Octreotide (OCT) has antiproliferative effects on many cells. The present study aimed to investigate the effect of OCT on antibiotic treatment of peritonitis. Material and Methods: Forty non-uremic female rats, were divided into four groups receiving no treatment (Control, n=12); a peritonitis group which received 1.5ml suspension of E.Coli (107CFU/ml)(E.Coli, n=12); an antibiotic group which received 1.5ml suspension of E.Coli (107CFU/ml)+antibiotic (AB, cefazoline 50 mg/kg)(E.Coli+AB, n=8) and a OCT group which received E.Coli+AB+50μg/kg OCT intraperitoneally (E.Coli+AB+OCT, n=8). After six hours, a onehour PET was performed with 3.86% glucose PD solution; and D1/D0 glucose, UF volume, dialysate cell count, dialysate protein and cytokines were determined. A bacteriological culture was performed for all dialysates. Results: E.Coli exposure causes peritonitis with an increase in permeability leading to UF failure. Antibiotic treatment partially preserves UF capacity. Peritonitis induced UF failure which was completely prevented by AB plus OCT treatment. Both treatments led to attenuation of UF failure by inhibiting local TGF b-1 production and decreasing dialysate cell count. Conclusion: In conclusion, adding OCT in dialysate, may help to prevent peritonitis induced UF failure and preserve peritoneal viability by inhibiting acute cytokines over-expression and cell infiltration during peritonitis. In the long-term, it can decrease peritoneal fibrosis.

Özet

Amaç: Ultrafiltrasyon (UF) yetmezliği genellikle periton diyalizi (PD) peritonitine eşlik eder. Oktreotid (OCT) birçok hücrede anti-proliferatif etki gösterir. Bu çalışmayla peritonitlerde antibiyotik tedavisine ilaveten kullanılan OCT’nin etkinliğini araştırmayı amaçladık. Yöntem ve Gereç: Üremik-olmayan kırk dişi sıçan, “tedavisiz grup (Kontrol, n=12)”, “peritonit grup 1.5ml E.Coli (107CFU/ml)(E.Coli, n=12)”, “antibiyotik grubu (AB)(E.Coli+AB, sefazolin 50mg/kg n=8)” ve “OCT grup, E.Coli+AB+50μg/kg OCT periton içine (E.Coli+AB+OCT, n=8)” olmak üzere dört gruba ayrıldı. Altı saat sonra 3.86% glukoz içeren PD solüsyonu ile bir saatlik PET yapıldı. D1/D0 glukoz, UF volümü, diyalizat hücre sayımı, diyalizat proteini ve sitokinler ölçüldü. Tüm diyalizat örneklerden bakteriyolojik kültür yapıldı. Bulgular: E.Coli maruziyeti permeabilite artışı ile UF yetersizliğine yol açar. Antibiyotik tedavisi UF kapasitesini kısmen korur. Peritonite bağlı UF yetersizliği A.B+OCT tedavisi ile tümden engellenmiştir. Her iki tedavi, lokal TGF $\beta$ 1 üretimini inhibe ederek ve diyalizat hücre sayısını azaltarak UF yetmezliğini azaltmıştır. Sonuç: Diyalizata OCT eklenmesi peritonit nedeniyle tetiklenen UF yetersizliğini engellemeye yardım edebilir, akut dönemde sitokinlerin aşırı ekspresyonunu ve peritonit sırasındaki hücre infiltrasyonunu inhibe ederek periton canlılığını korur. Uzun vadede periton fibrozunu azaltabilir.

🔖

Cite This Article

HÜR, E., ERTİLAV, M., BOZKURT, D., ARDA, B., SÖZMEN, E. Y., ŞEN, S., BAŞCI, A., AKÇİÇEK, F., DUMAN, Ş. (2011). Octreotide in addition to antibiotic treatment may prevent ultrafiltration failure in experimental peritonitis model. Ege Tıp Dergisi, Cilt: 50 - Sayı: 3, 167–173. https://ajindex.com/articles/222778

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (1)

  1. Bengt Rippe Peritoneal Dialysis: Principles, Techniques, and Adequacy. John Feehally, Jurgen Floege, Richard J. Johnson. Comprehensive Clinical Nephrology 3rd edition Phiedelphia Mosby Elsevier 2010:979-980 2. Krediet RT. The peritoneal membrane in chronic peritoneal dialysis. Kidney Int 55: 341-56, 1999 3. Tzamaloukas, AH. Inadequacy of dialysis and infectious complications of continuous ambulatory peritoneal dialysis (CAPD): Diagnosis, management and prevention. AKF Nephrol 8:29, 1991. 4. Mujais S, Nolph K, Gokal R et al. Evaluation and management of ultrafiltration problems in peritoneal dialysis. International Society for Peritoneal Dialysis Ad Hoc Committee on Ultrafiltration Management in Peritoneal Dialysis. Perit Dial Int. 2000;20 Suppl 4:S5-21. Review. 5. Pollock, CA, Ibels, LS, Hallett, MD. Loss of ultrafiltration in continuous ambulatory peritoneal dialysis (CAPD). Perit Dial Int 9:107, 1989 6. Margetts, PJ, Churchill, DN. Acquired ultrafiltration dysfunction in peritoneal dialysis patients. J Am Soc Nephrol 13:2787, 2002. 7. Stegmayr, BG. Beta-blockers may cause ultrafiltration failure in peritoneal dialysis patients. Perit Dial Int 17:541, 1997. 8. Honda K, Nitta K, Horita S, et al. Morphological changes in the peritoneal vasculature of patients on CAPD with ultrafiltration failure. Nephron 72: 171-6, 1996. 9. Rubin J, Herrera GA, Collins D. An autopsy study of the peritoneal cavity from patients on continuous ambulatory peritoneal dialysis. Am J Kidney Dis 18: 97-102, 1991. 10. Fracasso A, Baggio B, Ossi E, et al. Glycosaminoglycans prevent the functional and morphological peritoneal derangement in an experimental model of peritoneal fibrosis. Am J Kidney Dis 33: 105-10, 1999 11. Honda K, Nitta K, Horita S, et al. Accumulation of advanced glycation end products in the peritoneal vasculature of continuous ambulatory peritoneal dialysis patients with low ultra-filtration. Nephrol Dial Transplant 14: 1541-9, 1999 12. Falconi M, Vesentini S, Bassi C. Exocrine pancreatic response to SMS 2001-995. Ital J. Gastroenterol vol 23:3 p:156, 1991. 13. Fort E, Sauterau D, Silvain C, et al. A randomized trial of glypressin plus transdermal nitroglycerin versus octreotide in the control of acute variceal hemorrhage. Europ J Gastroenterol Hepatol vol 3 suppl 1 p:25, 1991. 14. Vinciguerra L, Contillo A, Bussci R, Parente A. Efficacy of octreotide+ 5 fluorouracil therapy in one patient with carcinoid syndrome. J Endoc Invest vol 13, suppl 1:235, 1990. 15.